Riskpilot← Back to searchSign inGet full accessRepligen Sweden AB
ABActiveOrg 5568690704Sankt Lars Väg 47Manufacture of basic pharmaceutical products · NACE 2110Est. 2011100-199 employees
Revenue 2024
SEK 587,7M
-31% vs 2023
EBITDA margin
71.6%
-28% vs 2023
Equity ratio
64.0%
Financial strength
Net profit 2024
SEK 488,2M
-9% vs 2023
| Revenue | SEK 587,7M | -31% |
| EBITDA | SEK 420,6M | -28% |
| Net profit | SEK 488,2M | -9% |
| Total assets | SEK 3,4B | +32% |
| Equity | SEK 2,2B | +29% |
| Employees | — | — |
Legal name
Repligen Sweden AB
Org number
5568690704
Legal form
Aktiebolag
NACE code
2110 · Manufacture of basic pharmaceutical products
Founded
26 oktober 2011
Share capital
SEK 50 000
Employees
100-199
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas var för sig av Bylund, James Richard Hestner, Per Anders Silfversparre, Lars Gustav
Company purpose
Bolaget skall direkt eller indirekt, tillhandahålla konsult- tjänster och bedriva forskning, utveckling, produktion, marknadsföring och försäljning av produkter och tjänster inom Life Science området, exempelvis inom läkemedel, bio- teknik och medicintekniska produkter, och därmed förenlig verksamhet.
Address
Sankt Lars Väg 47
Phone
+46709289894
Email
gusi@repligen.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | 308 838 | 359 489 | 455 358 | 452 359 | 683 186 | 724 875 | 852 740 | 587 721 |
| Staff expenses | — | — | — | — | — | — | — | — | — | — |
| EBITDA | 139 438 | 168 036 | 131 303 | 141 813 | 217 386 | 203 367 | 411 166 | 423 298 | 580 163 | 420 600 |
| Depreciation & amort. | — | — | — | — | — | — | — | — | — | — |
| EBIT | 139 438 | 168 036 | 131 303 | 141 813 | 217 386 | 203 367 | 411 166 | 423 298 | 580 163 | 420 600 |
| Net financials | −5 704 | −13 617 | −3 934 | −1 646 | −1 964 | −17 994 | 8 425 | 30 482 | 93 082 | 139 451 |
| Profit before tax | 133 734 | 154 419 | 127 369 | 140 299 | 215 526 | 192 562 | 419 618 | 453 784 | 673 256 | 560 058 |
| Tax | −29 477 | −34 032 | −28 101 | −30 952 | −46 181 | −41 249 | −86 765 | −93 264 | −138 743 | −71 831 |
| Net profit | 104 257 | 120 387 | 99 268 | 109 347 | 169 345 | 151 313 | 332 853 | 360 520 | 534 513 | 488 227 |
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 457 832 | 698 799 | 794 701 | 919 774 | 1 080 864 | 1 240 300 | 929 013 | 1 297 259 | 2 555 986 | 3 364 923 |
| Equity | 224 441 | 459 568 | 558 836 | 668 183 | 837 528 | 988 842 | 678 695 | 1 039 215 | 1 663 895 | 2 152 122 |
| Long-term debt | 192 048 | 192 048 | 192 048 | 192 048 | 192 048 | 192 048 | 186 003 | 186 003 | 806 856 | 948 808 |
| Short-term debt | 40 114 | 46 366 | 43 200 | 59 147 | 51 005 | 59 258 | 64 315 | 72 041 | 85 235 | 47 068 |
| Total debt | 232 162 | 238 414 | 235 248 | 251 195 | 243 053 | 251 306 | 250 318 | 258 044 | 892 091 | 995 876 |
EBITDA margin
71.6%
This company
15.8%
Market median
+353% vs market
20152024
Equity ratio
64.0%
This company
38.2%
Market median
+68% vs market
20152024
Return on equity
22.7%
This company
18.4%
Market median
+23% vs market
20152024
Net profit margin
83.1%
This company
8.1%
Market median
+926% vs market
20152024
Asset turnover
0.17×
This company
1.12×
Market median
-85% vs market
20152024
Debt / equity
0.56×
This company
0.62×
Market median
+10% vs market
20152024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Bolagsverket / SCB · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Bolagsverket / SCB · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Bolagsverket / SCB · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via Bolagsverket / SCB · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via Bolagsverket / SCB · Period 2015-01-01 – 2015-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
TM Chief Auditor | Chief Auditor | 2021 | — | — |
PA External Signatory | External Signatory | 2025 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2021 | — | — | |
| Board of Directors | 2023 | — | — | |
| Board of Directors | 2025 | — | — | |
| Chairman | 2021 | — | — | |
| Chairman | 2025 | — | — | |
| Board of Directors | 2023 | — | — | |
| Board of Directors | 2021 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
REPLIGEN CORPORATION | Company | 100.0% | 100.0% | 2025 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
REPLIGEN CORPORATION
Repligen Sweden AB (this company)Tantti Laboratories Inc.Repligen GmbhTANTTI LABORATORIES INC.REPLIGEN GMBHBoard members of Repligen Sweden AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Torbjörn Mikael Åberg | Chief Auditor | 0 companies |
| Per Anders Hestner | External Signatory | 0 companies |
| Christian Magnus Pedersen | Board of Directors | 0 companies |
| Lars Ola Martin Olsson Modig | Board of Directors | 0 companies |
| Lars Gustav Silfversparre | Board of Directors | 0 companies |
| Anthony Hunt | Chairman | 0 companies |
| James Richard Bylund | Chairman | 0 companies |
| Jon Snodgres | Board of Directors | 0 companies |
| Patrick Kennedy Martin | Board of Directors | 0 companies |